Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].

Tournigand C, Bengrine-Lefevre L.

Rev Med Interne. 2009 May;30(5):411-5. doi: 10.1016/j.revmed.2008.12.015. Epub 2009 Feb 23. Review. French.

PMID:
19231039
2.

[Novel molecular approaches in the therapy of advanced colorectal carcinoma].

Vanhoefer U.

Onkologie. 2003 Dec;26 Suppl 7:70-4. Review. German.

PMID:
14716146
3.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
4.

[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].

Assenat E, Ychou M.

Bull Cancer. 2009 Dec;96 Suppl:S41-6. doi: 10.1684/bdc.2009.1001. Review. French.

PMID:
20034869
5.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
6.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

7.

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2010 Jul;46(10):1829-34. doi: 10.1016/j.ejca.2010.03.017. Epub 2010 Apr 24.

PMID:
20418097
8.

Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.

Jackson C, Cunningham D.

Eur J Cancer. 2008 Mar;44(5):652-62. doi: 10.1016/j.ejca.2008.01.021. Epub 2008 Mar 3. Review.

PMID:
18313913
9.

[The development of the first line treatment of metastatic colorectal cancer (mCRC)].

Landherr L, Nagykálnai T.

Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Review. Hungarian.

10.

The role of targeted therapy in the treatment of colorectal cancer.

Goldberg RM, Hurwitz HI, Fuchs CS.

Clin Adv Hematol Oncol. 2006 Aug;4(8 Suppl 17):1-10; quiz 11-2. Review.

PMID:
17139241
11.

Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

Venook AP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. Review.

PMID:
19780248
12.

Chemotherapy and immunotherapy in metastatic colorectal cancer.

Loupakis F, Di Maio M, Falcone A.

N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6. No abstract available.

PMID:
19445032
13.

[Antibody treatment in colorectal cancer--what the surgeon needs to know].

Thalheimer A, Illert B, Reimer P, Bueter M, Thiede A, Gasser M, Fein M, Waaga-Gasser AM, Meyer D.

Zentralbl Chir. 2008 Apr;133(2):101-6. doi: 10.1055/s-2008-1004741. Review. German.

PMID:
18415895
14.

Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.

Peeters M, Balfour J, Arnold D.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):269-81. Review.

PMID:
19086328
15.

Integration of panitumumab into the treatment of colorectal cancer.

Gravalos C, Cassinello J, García-Alfonso P, Jimeno A.

Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17. Review.

PMID:
19616446
16.

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S.

Clin Cancer Res. 2009 May 1;15(9):3184-8. doi: 10.1158/1078-0432.CCR-08-2961. Epub 2009 Apr 14.

17.

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.

Lenz HJ, Chu E, Grothey A.

Clin Adv Hematol Oncol. 2008 Dec;6(12):1-13, 14-6.

PMID:
19378369
18.

Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.

Mahtani RL, Macdonald JS.

Oncologist. 2008 Jan;13(1):39-50. doi: 10.1634/theoncologist.2006-0049. Review.

19.

Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Normanno N, Tejpar S, Ciardiello F.

J Natl Cancer Inst. 2010 Apr 21;102(8):573; author reply 573-5. doi: 10.1093/jnci/djq064. Epub 2010 Mar 19. No abstract available.

PMID:
20305131
20.

Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I.

World J Gastroenterol. 2007 Nov 28;13(44):5867-76. Review.

Supplemental Content

Support Center